In drug sensitivity analysis and immune checkpoint analysis, the results showed that CDKN2A, DLAT, PDHA1 and GLS were negatively associated with some or most drugs in the cancer therapeutic response portal database, and the expression of DLST was positively correlated. Here, CDKN2A is linked to cancer.